An Extension Study to Evaluate the Efficacy and Safety of BMN 111 in Children With Achondroplasia
← catalyst calendarNCT03424018 · readout ≤ 1,776 d
Sponsored by BioMarin Pharmaceutical (industry) · BMRN — their whole pipeline →.
Phase
Phase 3
Status
Active, not recruiting
Study type
Interventional
Design
Na · None · Treatment
Enrollment
119actual
Sites
24
Countries
Australia, Germany, Japan +4
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2017-12-12 | actual | When the study began enrolling |
| Primary completion | Jun 2031 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Jun 2031 | estimated | The whole study's end, after follow-up |
| First posted | 2018-02-06 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-03-13 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Achondroplasia
Intervention
- Drug: BMN 111 — also filed as Vosoritide, Modified recombinant human C-type natriuretic peptide
Primary outcome
what the primary-completion date above is the date OFChange from baselines in mean annualized growth velocity
measured Through study completion, an average of 1 year
Publications
- PMID 39740666 — linked by the registry
- PMID 39305160 — linked by the registry
- PMID 38649657 — linked by the registry
Linked on the registry record. A “linked by the registry” entry is NLM's own automated PubMed match, not a claim by the sponsor that the paper reports this study.
Permalink · BMRN's whole pipeline · Catalyst calendar · Every registered study · What changed